Intelligent Bio Solutions Adds Quantum TM to 400+ Account Portfolio Utilizing Breakthrough Fingerprint Drug Testing
Intelligent Bio Solutions (INBS) announced that Quantum Traffic Management, a UK-based traffic management provider, has implemented INBS' Intelligent Fingerprinting Drug Testing Solution across its 10 nationwide sites. This transition from traditional saliva and urine testing to fingerprint sweat-based drug screening aims to enhance workplace testing efficiency and safety.
Quantum TM joins INBS's portfolio of more than 400 accounts across 19 countries. The fingerprint sweat-based system enables on-site drug screening without specialized staff or facilities, providing rapid results and improved operational efficiency. The company submitted an FDA 510(k) application in December 2024 and plans to enter the US market in 2025.
Intelligent Bio Solutions (INBS) ha annunciato che Quantum Traffic Management, un fornitore di gestione del traffico con sede nel Regno Unito, ha implementato la soluzione di testing per droghe tramite impronte digitali di INBS in tutti i suoi 10 siti nazionali. Questa transizione dai tradizionali test della saliva e dell'urina a test basati sul sudore delle impronte digitali mira a migliorare l'efficienza e la sicurezza dei test sul posto di lavoro.
Quantum TM si unisce al portafoglio di INBS di oltre 400 conti in 19 paesi. Il sistema basato sul sudore delle impronte digitali permette test delle droghe in loco senza la necessità di personale specializzato o strutture dedicate, fornendo risultati rapidi e migliorando l'efficienza operativa. L'azienda ha presentato una domanda FDA 510(k) nel dicembre 2024 e prevede di entrare nel mercato statunitense nel 2025.
Intelligent Bio Solutions (INBS) anunció que Quantum Traffic Management, un proveedor de gestión de tráfico con sede en el Reino Unido, ha implementado la Solución de Pruebas de Drogas por Huellas Dactilares de INBS en sus 10 sitios a nivel nacional. Esta transición de las pruebas tradicionales de saliva y orina a la detección de drogas basada en el sudor de las huellas dactilares tiene como objetivo mejorar la eficiencia y la seguridad en las pruebas en el lugar de trabajo.
Quantum TM se une al portafolio de INBS de más de 400 cuentas en 19 países. El sistema basado en el sudor de las huellas dactilares permite realizar pruebas de drogas en el lugar sin la necesidad de personal o instalaciones especializadas, proporcionando resultados rápidos y mejorando la eficiencia operativa. La compañía presentó una solicitud FDA 510(k) en diciembre de 2024 y planea ingresar al mercado estadounidense en 2025.
Intelligent Bio Solutions (INBS)는 영국에 본사를 둔 교통 관리 제공업체인 Quantum Traffic Management가 INBS의 지문 약물 검사 솔루션을 전국 10개 사이트에 도입했다고 발표했습니다. 기존의 침샘 및 소변 검사에서 지문 땀 기반 약물 검사로의 전환은 작업장 내 검사 효율성과 안전성을 향상시키기 위한 목적입니다.
Quantum TM은 INBS의 19개국에 걸쳐 400개 이상의 계정을 포함하는 포트폴리오에 합류합니다. 지문 땀 기반 시스템은 전문 인력이나 시설 없이도 현장에서 약물 검사를 가능하게 하여 신속한 결과와 개선된 운영 효율성을 제공합니다. 회사는 2024년 12월에 FDA 510(k) 신청서를 제출했으며, 2025년에는 미국 시장에 진입할 계획입니다.
Intelligent Bio Solutions (INBS) a annoncé que Quantum Traffic Management, un fournisseur de gestion du trafic basé au Royaume-Uni, a mis en œuvre la solution de dépistage des drogues par empreintes digitales d'INBS dans ses 10 sites à l'échelle nationale. Cette transition des tests traditionnels de salive et d'urine vers un dépistage des drogues basé sur la sueur des empreintes digitales vise à améliorer l'efficacité et la sécurité des tests sur le lieu de travail.
Quantum TM rejoint le portefeuille d'INBS de plus de 400 comptes dans 19 pays. Le système basé sur la sueur des empreintes digitales permet le dépistage des drogues sur site sans personnel ou installations spécialisés, offrant des résultats rapides et une efficacité opérationnelle améliorée. L'entreprise a soumis une demande FDA 510(k) en décembre 2024 et prévoit d’entrer sur le marché américain en 2025.
Intelligent Bio Solutions (INBS) gab bekannt, dass Quantum Traffic Management, ein im Vereinigten Königreich ansässiger Anbieter für Verkehrsmanagement, die intelligente Fingerabdruck-Drogentestlösung von INBS an seinen 10 Standorten im ganzen Land implementiert hat. Dieser Übergang von traditionellen Speichel- und Urintests zu einer auf Fingerabdruckschweiß basierenden Drogenerkennung zielt darauf ab, die Effizienz und Sicherheit von Tests am Arbeitsplatz zu verbessern.
Quantum TM tritt dem Portfolio von INBS mit mehr als 400 Konten in 19 Ländern bei. Das auf Fingerabdruckschweiß basierende System ermöglicht Drogentests vor Ort ohne spezialisiertes Personal oder Einrichtungen und bietet schnelle Ergebnisse sowie verbesserte betriebliche Effizienz. Das Unternehmen reichte im Dezember 2024 einen FDA 510(k)-Antrag ein und plant, 2025 in den US-Markt einzutreten.
- Expanded client base with addition of Quantum TM across 10 UK sites
- Strong market presence with 400+ accounts across 19 countries
- FDA 510(k) submission completed in December 2024
- Planned expansion into US market in 2025
- None.
Insights
The addition of Quantum TM to INBS's client portfolio represents a strategic milestone that validates the company's innovative fingerprint-based drug testing technology. The adoption by a major UK traffic management provider demonstrates the solution's practical advantages in time-sensitive industries where safety is paramount.
The expansion to 400+ accounts across 19 countries indicates strong market penetration and growing acceptance of INBS's technology. The fingerprint sweat-based system's key differentiators - rapid results, non-invasive nature and elimination of specialized staff requirements - address critical pain points in workplace drug testing.
The timing of this client acquisition is particularly significant as INBS prepares for US market entry in 2025. The US workplace drug testing market, valued at approximately $4.5 billion, presents a substantial growth opportunity. The recent FDA 510(k) submission in December 2024 suggests a well-planned regulatory strategy, though approval timelines typically range from 3-6 months.
Key market drivers supporting INBS's growth trajectory include:
- Increasing workplace safety regulations across industries
- Rising substance abuse rates driving demand for efficient testing solutions
- Growing preference for non-invasive, rapid testing methods
- Shift towards in-house testing to reduce costs and improve efficiency
While the company's technology shows promise, investors should monitor:
- FDA approval progress and timeline
- Speed of US market penetration
- Revenue conversion from the existing client base
- Competition from established players in the US market
Quantum Traffic Management transitions from saliva and urine testing to non-invasive, in-house fingerprint sweat-based drug screening
Most recent client added to INBS’s portfolio of more than 400 accounts across the globe, as the Company plans entry into the US market in 2025
NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Quantum Traffic Management (“Quantum TM”), a leading UK-based traffic management provider, has adopted INBS’ Intelligent Fingerprinting Drug Testing Solution across its 10 nationwide sites to increase workplace testing efficiency and safety.
With over 30 years of industry experience, Quantum TM operates across the utilities, highways, rail, local authority, and events sectors. Previously, Quantum TM relied on saliva and urine testing through external occupational health providers; however, the delays and inefficiencies associated with these methods prompted the company to explore a quicker and more hygienic alternative. INBS’ fingerprint sweat-based system enables Quantum TM to conduct on-the-spot drug screening in-house, facilitating rapid decision-making and improved operational efficiency.
“The Intelligent Fingerprinting Drug Testing Solution provides us with greater control when it comes to drug testing. Having previously faced delays with our former saliva and urine drug testing methods, we needed to find an effective solution that we could manage in-house and increase our testing productivity,” said Scott Powell, Managing Director at Quantum TM. “Intelligent Bio Solutions’ technology enables us to do this, and we have already improved our testing efficiency with rapid, non-invasive screening.”
INBS’ Intelligent Fingerprinting Drug Screening System enables organizations to conduct efficient and accurate drug screening tests without requiring specialized staff or facilities. Its ability to provide rapid on-site results eliminates many of the challenges associated with traditional testing methods.
With over 400 accounts across 19 countries, INBS continues to lead the evolution of drug screening technology, serving industries including construction, manufacturing, transport, and logistics. With the Company’s recent FDA 510(k) submission in December 2024 and with plans to enter the US market in 2025, INBS is poised to leverage the rapidly expanding global POC drug screening market.
About Quantum Traffic Management
Quantum Traffic Management specializes in full-service bespoke traffic management solutions throughout the United Kingdom, catering to the utilities, highways, rail, local authorities, and event sectors. With over 30 years of experience in a wide range of services, including 12AB (high-speed) and 12D (rural and urban roads), the company consistently delivers high-quality, tailored solutions with a strong focus on health and safety.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc/
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
FAQ
What is the current global reach of INBS's drug testing solution?
When does INBS plan to enter the US market?
How does INBS's fingerprint drug testing differ from traditional methods?
What benefits did Quantum TM report after implementing INBS's drug testing solution?
When did INBS submit their FDA 510(k) application?
